Filtered By:
Cancer: Non-Small Cell Lung Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 1077 results found since Jan 2013.

Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211041453. doi: 10.1177/15330338211041453.ABSTRACTDelivery of small-interfering RNA (siRNA) has been of great interest in the past decade for effective gene silencing. To overcome synthetic and regulatory challenges posed by nanoparticle-mediated siRNA delivery, antibody-siRNA conjugate (ARC) platform is emerging as a potential siRNA delivery system suitable for clinical translation. Herein, we have developed a delivery technology based on the ARC platform for stable delivery of siRNA called as Gelatin-Antibody Delivery System (GADS). In GADS, positively charged gelatin act...
Source: Cell Research - September 20, 2021 Category: Cytology Authors: K Sreedurgalakshmi R Srikar K Harikrishnan Lakshmi Srinivasan Reena Rajkumari Source Type: research

Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang, Dong Zhou, Yin Dai, Yanqi Li, Jiang Wu, Quanxing Liu, Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research

Abstract 4571: Antitumor effects of an antibody (cetuximab)-targeted nanoparticle containing siRNA against EGFR
Conclusions: NPs containing full antibodies as targeting agents and siRNA payloads can be formulated into well defined, stable experimental therapeutics. The NP system used here has a pH-tunable 5-nPBA that allows for targeting and stabilizing the NP at a physiologic pH of 7.4. The targeting agent and PEG coating is able to detach from the NP at acidic pH like those found in endosomes, enabling the siRNA payload to escape and reach its site of action within the cell. These NPs produce significant tumor regression in vivo that is superior to CTX alone. Citation Format: Dorothy W. Pan, Mark E. Davis. Antitumor effects of an ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Pan, D. W., Davis, M. E. Tags: Experimental and Molecular Therapeutics Source Type: research

285 * nanoliposomal-mediated sirna targeting of ea.hy926: a promising delivery method
Conclusion: We demonstrated that using optimal nanoliposomal complexes for effective human endothelial cell (Ea.hy926) targeting leads to high transfection efficiency and significant suppression of the protein level. Overcoming the siRNA extracellular instability with cell viability being unchanged shows that the developed delivery system may become a promising therapeutic strategy for non-small-cell lung carcinoma.
Source: Interactive CardioVascular and Thoracic Surgery - September 23, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Nemeth, A., Nolte-Karayel, A., Stoleriu, M. G., Mustafi, M., Steger, V., Schlensak, C., Wendel, H. P., Walker, T. Tags: Basic science Source Type: research

Study on co-delivery of pemetrexed disodium and Bcl-2 siRNA by poly- γ-glutamic acid-modified cationic liposomes for the inhibition of NSCLC
Drug Dev Ind Pharm. 2023 Feb 20:1-18. doi: 10.1080/03639045.2023.2182125. Online ahead of print.ABSTRACTDue to the complexity of pathophysiology of non-small cell lung cancer (NSCLC) and susceptibility of single chemotherapy to drug resistance, the combination of drugs and small interfering RNA (siRNA) may produce desired therapeutic effect on NSCLC through action of multiple pathways. We designed to develop poly-γ-glutamic acid-modified cationic liposomes (γ-PGA-CL) to co-deliver pemetrexed disodium (PMX) and siRNA to treat NSCLC. Firstly, γ-PGA was modified on surface of PMX and siRNA co-loaded cationic liposomes by e...
Source: Drug Development and Industrial Pharmacy - February 21, 2023 Category: Drugs & Pharmacology Authors: Huang Xiaoyu Song Ruonan Wang Xiao Kongfang He Rumeng Shan Xie Fei Guihua Huang Source Type: research

Cabazitaxel-loaded human serum albumin nanoparticles combined with TGF β-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer
ConclusionsThe antitumor effect of CTX-HSA-NPs on paclitaxel-resistant NSCLC was higher than that of CTX-Tween, and the toxicity was lower than that of CTX-Tween. TGF β-1 siRNA LNP can treat paclitaxel-resistant NSCLC by inhibiting the express ofTGF β-1 mRNA. The combined treatment of TGF β-1 siRNA LNP and CTX-HSA-NPs could effectively improve the antitumor efficacy of paclitaxel-resistant NSCLC. A combination therapy of chemotherapy and nucleic acid drugs could be an effective approach for treating paclitaxel-resistant NSCLC.
Source: Cancer Nanotechnology - July 29, 2023 Category: Cancer & Oncology Source Type: research

086 * A NEW STRATEGY IN THE TREATMENT OF CHEMORESISTANT LUNG ADENOCARCINOMA VIA siRNA SPECIFIC SILENCING OF SRF, E2F1, SURVIVIN, HIF AND STAT 3
Conclusions: Our study proposed a new alternative in the treatment of chemoresistant NSCLC. Via siRNA specific silencing complex an accurate suppression of various chemoresistant cell lines can be achieved. Therefore, siRNA might represent an effective transient individualized regimen in the treatment of NSCLC as well an important platform for new chemotherapeutics.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Stoleriu, M. G., Steger, V., Mustafi, M., Schneider, W., Wendel, H. P., Walker, T., Schlensak, C. Tags: Thoracic experimental Source Type: research

siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells.
In this study, we developed an EGFR-scFv-arginine nonamer peptide fusion protein, s-9R, as an siRNA carrier. Here, we show that s-9R effectively and specifically delivers EGFR-siRNAs, KRAS-siRNA and MET-siRNA into NSCLC cells and silences the expression of target genes. The sensitivity of NSCLC cells to gefitinib was restored after treatment with the s-9R/siRNA complex, and the apoptosis rates of the treated cells were significantly higher than those of the control groups. Furthermore, the co-administration of s-9R/siRNA and gefitinib successfully suppressed the progression of H1975 xenograft tumors and extended the life s...
Source: Biomaterials - October 23, 2015 Category: Materials Science Authors: Lu Y, Liu L, Wang Y, Li F, Zhang J, Ye M, Zhao H, Zhang X, Zhang M, Zhao J, Yan B, Yang A, Feng H, Zhang R, Ren X Tags: Biomaterials Source Type: research

The influence of oligospermine architecture on their suitability for siRNA delivery.
Abstract Spermines are naturally abundant polyamines, which partially condense nucleic acids and exhibit the "proton-sponge effect" in an acidic environment. However, spermine shows limited transfection efficiency of nucleic acids due to its low molecular weight. Therefore, spermines need to be modified to be used as non-viral vectors for nucleic acids. Here, we synthesized linear bisspermine, and linear and dendritic tetraspermine with different molecular architecture. These oligospermines have been self-assembled into polyplexes with siRNA. The structure-activity relationship of the oligospermines was evaluated ...
Source: Biomacromolecules - February 19, 2014 Category: Biochemistry Authors: Elsayed M, Corrand V, Kolhatkar V, Xie Y, Kim NH, Kolhatkar R, Merkel OM Tags: Biomacromolecules Source Type: research

A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3 BASIC SCIENCE
CONCLUSIONS In our study, we emphasized that siRNA interference might represent a productive platform for further research in order to investigate whether a new regimen in the treatment of multiresistant non-small-cell lung cancer could be established in vivo in the context of a multimodal cancer therapy.
Source: European Journal of Cardio-Thoracic Surgery - October 10, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Stoleriu, M. G., Steger, V., Mustafi, M., Michaelis, M., Cinatl, J., Schneider, W., Nolte, A., Kurz, J., Wendel, H. P., Schlensak, C., Walker, T. Tags: Lung - cancer, Lung - transplantation, Mediastinum, Pleura, Cardiac - pharmacology, Lung - basic science Source Type: research

siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells.
Authors: He Z, Huang C, Lin G, Ye Y Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been found to be involved in multiple cancers. However, the effect of small interfering RNA (siRNA)‑induced knockdown of TRAF6 on the biological behaviors of cancer cells remains unknown. Thus, the present study aimed to investigate the effect of siRNA-induced knockdown of TRAF6 on the biological behaviors of human lung cancer SPC-A1 cells. The expression of TRAF6 was determined in human lung adenocarcinoma A549, non-small cell lung cancer H1650, human airway epithelial Calu-3 and human lung cancer SPC-A1 ...
Source: Oncology Reports - February 9, 2016 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research